Neuren Pharmaceuticals | NEU - Cash And Equivalent


Neuren Pharmaceuticals reported AUD5.91M in Cash and Equivalent for its fiscal semester ending in June of 2025.





Cash And Equivalent Change Date
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Avita Medical AUD 10.24M 1.98M Dec/2025
Clinuvel Pharmaceuticals AUD 35.2M 3.62M Jun/2024
Dianthus Therapeutics USD 627.67M 576.58M Mar/2026
Genetic Signatures AUD 7.47M 33.32M Jun/2025
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Medical Developments International AUD 17.84M 219K Jun/2025
Neuren Pharmaceuticals AUD 5.91M 2.76M Jun/2025
Organon & Co USD 1.12B 542M Mar/2026
Paradigm Biopharmaceuticals AUD 16.82M 1M Jun/2025
PYC Therapeutics AUD 153.05M 103.8M Jun/2025
Starpharma Holdings AUD 15.41M 4.87M Jun/2025
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Telix Pharmaceuticals AUD 207.16M 503.19M Jun/2025
Viatris USD 1.8B 481.8M Mar/2026
Xeris Pharmaceuticals USD 111.75M 708K Mar/2026